Browse PIAS3

Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Nucleus speckle Note=Colocalizes with MITF in the nucleus. Colocalizes with GFI1 in nuclear dots. Colocalizes with SUMO1 in nuclear granules.
Domain PF14324 PINIT domain
PF02891 MIZ/SP-RING zinc finger
Function

Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway and the steroid hormone signaling pathway. Involved in regulating STAT3 signaling via inhibiting STAT3 DNA-binding and suppressing cell growth. Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678, PubMed:9388184). Sumoylates CCAR2 which promotes its interaction with SIRT1 (PubMed:25406032). Diminishes the sumoylation of ZFHX3 by preventing the colocalization of ZFHX3 with SUMO1 in the nucleus (PubMed:24651376).

> Gene Ontology
 
Biological Process GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0033233 regulation of protein sumoylation
GO:0033234 negative regulation of protein sumoylation
GO:0033235 positive regulation of protein sumoylation
GO:0042391 regulation of membrane potential
GO:0045838 positive regulation of membrane potential
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
Molecular Function GO:0008022 protein C-terminus binding
GO:0015459 potassium channel regulator activity
GO:0016247 channel regulator activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0019789 SUMO transferase activity
GO:0047485 protein N-terminus binding
Cellular Component GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-73894: DNA Repair
R-HSA-5696395: Formation of Incision Complex in GG-NER
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-392499: Metabolism of proteins
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-3232118: SUMOylation of transcription factors
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PIAS3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PIAS3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18676737GlioblastomaPromote immunityInhibition of PIAS3 resulted in enhanced glioblastoma cellular proliferation. Conversely, PIAS3 overexpression inhibited STAT-3 transcriptional activity, expression of STAT-3-regulated genes, and cell proliferation. We propose that the loss of PIAS3 in GBM contributes to enhanced STAT-3 transcriptional activity and subsequent cell proliferation.
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PIAS3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PIAS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.380.0817
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4810.793
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3020.814
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3350.294
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5760.792
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0360.99
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2540.479
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0930.949
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6880.655
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0050.501
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0950.303
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0240.773
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PIAS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIAS3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIAS3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIAS3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIAS3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PIAS3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PIAS3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPIAS3
Nameprotein inhibitor of activated STAT, 3
Aliases FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PIAS3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.